RBM38 plays a tumor-suppressor role via stabilizing the p53-mdm2 loop function in hepatocellular carcinoma

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  R. Cardiff,et al.  Mice deficient in Rbm38, a target of the p53 family, are susceptible to accelerated aging and spontaneous tumors , 2014, Proceedings of the National Academy of Sciences.

[3]  Yanping Zhang,et al.  MDM2-p53 pathway in hepatocellular carcinoma. , 2014, Cancer research.

[4]  Wenbin Zhou,et al.  RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer , 2014, BMC Cancer.

[5]  Haiyang Xie,et al.  Long Non-Coding RNA HOTAIR Promotes Cell Migration and Invasion via Down-Regulation of RNA Binding Motif Protein 38 in Hepatocellular Carcinoma Cells , 2014, International journal of molecular sciences.

[6]  J.-L. Huang,et al.  Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. , 2014, Carcinogenesis.

[7]  I. Rusyn,et al.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma. , 2014, Cancer letters.

[8]  Xinbin Chen,et al.  Regulation of Mdm2 mRNA Stability by RNA-binding Protein RNPC1 , 2013, Oncotarget.

[9]  Darjus F. Tschaharganeh,et al.  Non-Cell-Autonomous Tumor Suppression by p53 , 2013, Cell.

[10]  M. Kudo,et al.  Recent Advancements in Comprehensive Genetic Analyses for Human Hepatocellular Carcinoma , 2013, Oncology.

[11]  Xinbin Chen,et al.  MDM2 Expression Is Repressed by The RNA-Binding Protein RNPC1 via mRNA Stability , 2012, Oncogene.

[12]  Yanhong Zhang,et al.  p73 Expression Is Regulated by RNPC1, a Target of the p53 Family, via mRNA Stability , 2012, Molecular and Cellular Biology.

[13]  Seong-Jun Cho,et al.  Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. , 2011, Genes & development.

[14]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[15]  Xinbin Chen,et al.  RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability , 2010, Proceedings of the National Academy of Sciences.

[16]  Yi Sun,et al.  Targeting p53 for Novel Anticancer Therapy. , 2010, Translational oncology.

[17]  Seong-Jun Cho,et al.  RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability , 2010, Nucleic acids research.

[18]  Jung Hur,et al.  Emerging roles of RNA and RNA-binding protein network in cancer cells. , 2009, BMB reports.

[19]  Jun Yong Park,et al.  MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. , 2008, Carcinogenesis.

[20]  A. Hinnebusch,et al.  New modes of translational control in development, behavior, and disease. , 2007, Molecular cell.

[21]  K. Vousden,et al.  p53: new roles in metabolism. , 2007, Trends in cell biology.

[22]  W. Watford,et al.  Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. , 2007, The Journal of clinical investigation.

[23]  C. Harris,et al.  TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer , 2007, Oncogene.

[24]  Carlos Cordon-Cardo,et al.  Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas , 2007, Nature.

[25]  S. Boyault,et al.  Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.

[26]  N. Kato,et al.  MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006, Clinical Cancer Research.

[27]  J. Yisraeli.  VICKZ proteins: a multi‐talented family of regulatory RNA‐binding proteins , 2005, Biology of the cell.

[28]  Y. Audic,et al.  Post‐transcriptional regulation in cancer , 2004, Biology of the cell.

[29]  M. Swanson,et al.  hnRNP complexes: composition, structure, and function. , 1999, Current opinion in cell biology.

[30]  M. Oren,et al.  A functional p53-responsive intronic promoter is contained within the human mdm2 gene. , 1995, Nucleic acids research.

[31]  F. Imazeki,et al.  p53 gene mutations and 17p allelic deletions in hepatocellular Carcinoma from Japan , 1993, Cancer.

[32]  Bert Vogelstein,et al.  Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53 , 1993, Nature.

[33]  M. Oren,et al.  mdm2 expression is induced by wild type p53 activity. , 1993, The EMBO journal.

[34]  A. Levine,et al.  The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation , 1992, Cell.

[35]  D. Lane,et al.  Reactivation of p53: from peptides to small molecules. , 2011, Trends in pharmacological sciences.

[36]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[37]  N. Kato,et al.  MDM 2 Promoter SNP 309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C , 2006 .

[38]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[39]  C. Burd,et al.  hnRNP proteins and the biogenesis of mRNA. , 1993, Annual review of biochemistry.